French connected-health company Withings used the IFA Berlin trade show in early September 2026 to unveil StethO Sense, a new AI-powered feature for its BeamO multi-scanner device that listens to heart and lung sounds and flags potential abnormalities within seconds. The feature, reported by Gadgets & Wearables and other outlets covering the show, is scheduled to roll out to Withings+ subscribers starting October 1, 2026, extending the company’s push to turn consumer gadgets into home diagnostic tools.
What StethO Sense Actually Does
BeamO, first launched by Withings in 2024, is a palm-sized multi-scanner that already measures body temperature, blood oxygen, heart rate, and single-lead ECG readings by pressing the device against the skin. StethO Sense adds a digital stethoscope function: users hold BeamO against their chest or back, and the device records heart and lung sounds that are then processed by an AI model trained to detect irregular rhythms, murmurs, and abnormal breathing patterns such as wheezing or crackling associated with conditions like asthma or fluid buildup. Results are returned in the Withings app within seconds, alongside plain-language guidance on whether a finding warrants a follow-up with a doctor.
Part of a Broader Home-Diagnostics Push
The announcement came alongside continued rollout of Withings’ Body Scan 2 smart scale, first shown at CES 2026, which uses six-lead ECG and bioelectrical impedance sensors to flag hypertension risk and track more than 60 biomarkers spanning cardiovascular function, vascular health, and cellular composition. Together, the products reflect a strategy Withings has pursued since its founding in 2009: shifting diagnostic-grade sensing out of clinics and into bathroom cabinets and living rooms, positioning the company against both traditional medical device makers and consumer wearable rivals like Apple and Oura that have moved into similar territory with heart-rhythm and metabolic-health features.
Why AI Listening Tools Are Gaining Traction
Digital stethoscopes and AI-assisted auscultation have been used in clinical settings for several years — companies like Eko Health have FDA-cleared AI algorithms that detect heart murmurs and atrial fibrillation from stethoscope recordings, and cardiologists have published peer-reviewed studies showing AI models can catch subtle valve abnormalities that inexperienced clinicians miss. Withings is betting that shrinking that capability into a consumer device, paired with its existing base of BeamO and scale users, can catch early warning signs of cardiovascular and respiratory conditions before people ever see a doctor, particularly for underdiagnosed conditions like heart valve disease that often go unnoticed until symptoms are severe.
The Caveats Doctors Are Raising
Cardiologists and regulatory specialists caution that consumer AI auscultation tools face a much lower evidentiary bar than clinical-grade devices unless they seek FDA clearance, and Withings has not yet said whether StethO Sense will carry a medical-device classification in the U.S. or Europe. Physicians who have reviewed similar consumer heart-sound features note that ambient noise, imprecise device placement, and the wide range of "normal" heart and lung sounds across different body types can generate false positives that send healthy users into unnecessary anxiety and follow-up appointments, or false negatives that offer false reassurance. Withings has said the feature is intended as a screening aid rather than a diagnostic tool, echoing language used by other wellness-adjacent AI health features to stay outside stricter medical regulation. That framing matters commercially as much as legally: a device marketed strictly as a wellness aid can reach consumers faster and without the clinical-trial burden that a cleared medical device requires, but it also means Withings cannot claim StethO Sense diagnoses any specific condition, only that it flags patterns worth discussing with a physician.
How It Compares to Rivals
Withings is not alone in chasing AI-assisted cardiovascular sensing. Apple Watch’s ECG feature and irregular rhythm notifications, cleared by the FDA years ago, remain the most widely used consumer heart tool, while Eko Health’s clinical-grade digital stethoscopes are already deployed in primary care offices with physician-facing AI murmur detection. Samsung and Oura have both leaned toward optical and biosignal sensing — heart rate variability, blood oxygen, and skin temperature — rather than acoustic analysis, leaving StethO Sense as one of the first mass-market consumer products built specifically around AI-interpreted heart and lung sounds rather than pulse-based metrics. That relative novelty is both an opportunity for Withings to differentiate BeamO and a risk, since sound-based analysis has less real-world consumer usage data behind it than optical sensing does.
What’s Next
StethO Sense will launch as part of the paid Withings+ subscription tier when it goes live on October 1, 2026, initially for existing BeamO owners rather than as a standalone hardware release. Withings executives have said future updates could expand the AI model to track sound patterns over time, alerting users to gradual changes rather than just single-reading snapshots — a feature the company argues could be more clinically useful than a one-off scan. As wearable and home-device makers race to add AI-driven cardiovascular monitoring, StethO Sense adds a new category, sound analysis, to a field that has so far been dominated by optical heart-rate sensors and single-lead ECG, setting up a broader competitive question over which sensing modality will prove most reliable for catching disease early outside a clinical setting.
Photo: DariuszSankowski / PIXABAY via Pixabay
